MMCM
NTLA icon

Murphy & Mullick Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Murphy & Mullick Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-167
Closed -$2.14K – 717
2026
Q1 		$2.14K Sell
167
-11
-6% -$140 ﹤0.01% 597
2025
Q4 		$1.6K Hold
178
– – ﹤0.01% 617
2025
Q3 		$3.07K Sell
178
-29
-14% -$357 ﹤0.01% 573
2025
Q2 		$2.41K Sell
207
-58
-22% -$476 ﹤0.01% 574
2025
Q1 		$1.88K Hold
265
– – ﹤0.01% 574
2024
Q4 		$3.09K Buy
+265
New +$4.14K ﹤0.01% 537

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Murphy & Mullick Capital Management's NTLA Position: Q2 2026 in Review

Murphy & Mullick Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 167 shares — an estimated $2.14K sold.

Murphy & Mullick Capital Management first reported a position in NTLA in Q4 2024 and held it in 6 quarters. The position peaked at $3.09K in Q4 2024. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Murphy & Mullick Capital Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 167 Intellia Therapeutics shares in Q2 2026, an estimated $2.14K.
  • Murphy & Mullick Capital Management first reported a position in Intellia Therapeutics in Q4 2024 and held it in 6 quarters.
  • Murphy & Mullick Capital Management's Intellia Therapeutics position peaked at $3.09K in Q4 2024.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.